Bortezomib for refractory autoimmunity in pediatrics

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 10, 2014, Pages 1641-1665

  Khandelwal, Pooja ^a   Davies, Stella M ^a   Grimley, Michael S ^a   Jordan, Michael B ^a   Curtis, Brian R ^b   Jodele, Sonata ^a   Marsh, Rebecca ^a   Filipovich, Alexandra J ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune cytopenias; Bortezomib; Proteasome inhibition; Refractory autoimmunity

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; HAPTOGLOBIN; IMMUNOGLOBULIN; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ADOLESCENT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; CELLULITIS; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CYTOPENIA; FEBRILE NEUTROPENIA; HEMOLYTIC ANEMIA; HUMAN; NAUSEA; NEUTROPENIA; PLASMAPHERESIS; PRESCHOOL CHILD; RETICULOCYTE COUNT; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; AUTOIMMUNITY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; INFANT; MALE; PATHOLOGY; PLASMA CELL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; BORONIC ACIDS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; NEUTROPENIA; PLASMA CELLS; PLASMAPHERESIS; PROTEASOME INHIBITORS; PYRAZINES; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 84912521911     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.032     Document Type: Article

References (24)

1. Page K.M., Mendizabal A.M., Prasad V.K., et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant 2008, 14:1108-1117.
2. Sanz J., Arriaga F., Montesinos P., et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant 2007, 39:555-561.
3. Dvorak C.C., Bollard C.M., El-Bietar J., Filipovich A. Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD. Biol Blood Marrow Transplant 2012, 18:S101-S110.
4. Horn B., Viele M., Mentzer W., et al. Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant 1999, 24:1009-1013.
5. O'Brien T.A., Eastlund T., Peters C., et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol 2004, 127:67-75.
6. Hiepe F., Dorner T., Hauser A.E., et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011, 7:170-178.
7. Hoyer B.F., Moser K., Hauser A.E., et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. JExp Med 2004, 199:1577-1584.
8. Mulder A., Heidt S., Vergunst M., et al. Proteasome inhibition profoundly affects activated human B cells. Transplantation 2013, 95:1331-1337.
9. Ludwig H., Khayat D., Giaccone G., Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005, 104:1794-1807.
10. Frohlich K., Holle J.U., Aries P.M., et al. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 2011, 70:1344-1345.
11. Eckman P.M., Thorsgard M., Maurer D., et al. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Clin Transplant 2009, 475-478.
12. Everly J.J., Walsh R.C., Alloway R.R., Woodle E.S. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009, 14:662-666.
13. Everly M.J., Everly J.J., Susskind B., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761.
14. Morrow W.R., Frazier E.A., Mahle W.T., et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012, 93:319-324.
15. Raghavan R., Jeroudi A., Achkar K., et al. Bortezomib in kidney transplantation. JTransplant 2010, Available at: http://dx.doi.org/10.1155/2010/698594.
16. Sadaka B., Alloway R.R., Woodle E.S. Clinical and investigational use of proteasome inhibitors for transplant rejection. Exp Opin Invest Drugs 2011, 20:1535-1542.
17. Trivedi H.L., Terasaki P.I., Feroz A., et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009, 87:1555-1561.
18. Walsh R.C., Everly J.J., Brailey P., et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010, 89:277-284.
19. Woodle E.S., Alloway R.R., Girnita A. Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant 2011, 16:434-438.
20. Woodle E.S., Walsh R.C., Alloway R.R., et al. Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant 2011, 15:548-556.
21. Moreau P., Pylypenko H., Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
22. Fairfax K.A., Kallies A., Nutt S.L., Tarlinton D.M. Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol 2008, 20:49-58.
23. Everly M.J., Terasaki P.I., Hopfield J., et al. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation 2010, 90:1493-1498.
24. Reardon J.E., Marques M.B. Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia. Am J Clin Pathol 2006, 125(Suppl):S71-S77.